Guidelines for Use
Our guideline named ADAGRASIB (Krazati) requires the following rule(s) be met for approval:
- You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
- You are 18 years of age or older
- Your cancer has a KRAS G12C mutation (a type of mutation) as determined by a Food and Drug Association (FDA)-approved test
- You have received at least one prior systemic therapy
Rationale
To ensure appropriate use of Krazati consistent with FDA approved indication.
Indications for Use
Krazati is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
Dosage and Administration
Recommended dosage: 600 mg orally once daily.
References
Krazati [Prescribing Information]. San Diego, CA: Mirati Therapeutics, Inc., December 2022.